Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Inhaled Oxytocin vs IM/IV Oxytocin in Third Stage Labour and Non-pregnant Women
NCT02999100Phase 1Terminated
- Sponsor
- GSK
- Start
- Nov 2016
- Primary completion
- Mar 2019
- Modality
- Peptides
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of oxytocin in postpartum hemorrhage (PPH) (3 arms), sponsored by GSK. Primary endpoints: Plasma Concentration Time Profile of Oxytocin at 4 hours, Maximum Observed Plasma Concentration of Oxytocin at Day 1 and 9 more. Started Nov 2016; status: terminated.
02
Drugs
oxytocin
03
Conditions
postpartum hemorrhage (PPH)
Beyond the preview
Go deeper on NCT02999100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02999100.